Budget Amount *help |
¥3,510,000 (Direct Cost: ¥2,700,000、Indirect Cost: ¥810,000)
Fiscal Year 2017: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000)
Fiscal Year 2016: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2015: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
Outline of Final Research Achievements |
Levodopa (DOPA) is currently the most used treatment for Parkinson's disease. We have hypothesis that DOPA is a neurotransmitter in the brain. In this study, we demonstrated that DOPA potentiates the action of glutamate in the nucleus tractus solitarii, which controls central blood pressure regulation. We also identified the role of DOPA in cardiovascular regulation. We demonstrated that DOPA augments the action of the adrenergic α1 receptor through a DOPA receptor GPR143. It suggested that this mechanism may be involved in diurnal variation of blood pressure. These findings indicate that DOPA plays an important role in physiological blood pressure control.
|